Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 8/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 8/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.39 |
| ▸ | PARP1 | P09874 | 4/20 | 0.37 |
| ▸ | C1R | P00736 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2170605 | 0.82 | PDE4B (0.53) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL2170836 | 0.81 | PDE4B (0.52) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL2170616 | 0.80 | BTK (0.42) | PDE4BPDE4APDE4CPDE4DP2RX7 | |
| SCHEMBL3122136 | 0.72 | PDE4B (0.56) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL2847415 | 0.70 | PDE4B (1.00) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL29613350 | 0.70 | PARP1 (0.56) | P2RX7PRMT1TNKSTNKS2PARP2 | |
| SCHEMBL1536501 | 0.70 | PARP1 (0.56) | P2RX7PRMT1TNKSTNKS2PARP2 | |
| SCHEMBL2170590 | 0.68 | PDE4B (0.52) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL3118080 | 0.68 | PDE3A (0.70) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL2170898 | 0.68 | PDE4B (0.50) | PDE4BPDE3APDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348018-A1 | HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| WO-2010035745-A1 | HETEROCYCLIC BIARYL DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | 杏林製薬株式会社 (JP) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178041-A1 | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | PDE3A, PDE2A, PDE3B | PDE4B 6/4885PDE3A 1/4885PDE4A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.